Two novel biologics license application (BLA) submissions lead the US FDA review and approval news this week, one from pharma giant AstraZeneca PLC and one from relative newcomer Provention Bio, Inc., while AbbVie Inc.’s Rinvoq and Johnson & Johnson/Bayer AG’s Xarelto were submitted for new indications. Ophthalmic specialist Santen Pharmaceutical Co., Ltd.’s bid for approval for an eye drop formulation of the immunosuppressant cyclosporine.
Meanwhile, the quiet season for FDA approvals continues. The agency cleared a new indication for AstraZeneca’s direct oral anticoagulant Brilinta...





